<DOC>
	<DOCNO>NCT01290393</DOCNO>
	<brief_summary>This study ass risk spontaneous abortion week 1-19 gestation , pregnancy outcome , Exposed vaccinated cohort , i.e . woman last menstrual period 30 day 90 day dose CERVARIX , compare Non-exposed vaccinated cohort , i.e . woman last menstrual period 120 day 18 month last CERVARIX GARDASIL dose .</brief_summary>
	<brief_title>Post-marketing Study Assess Safety CERVARIX When Used United States Canada</brief_title>
	<detailed_description>The present study conduct OTIS ( Organization Teratology Information Specialists ) network . OTIS non-profit organization specialise assess exposure pregnancy dedicate provide accurate evidence-based , clinical information patient health care professional exposures pregnancy lactation . OTIS base voluntary phone call . Women call question concern risk potentially associate kind exposure pregnancy breastfeeding , include medication , chemical , pesticide , disease , infection , vaccination .</detailed_description>
	<mesh_term>Abortion , Spontaneous</mesh_term>
	<criteria>For Exposed vaccinated cohort : Written inform consent , assent case minor , obtain subject/from parent ( ) /legally acceptable representative ( ) subject . Aged , include , 15 25 year age . Residing within US Canada . Subjects receive least one dose CERVARIX . Gestational age inclusion 19 complete week ( i.e . 133 day gestation ) less . Last menstrual period 30 day 90 day dose CERVARIX maximum 20 % subject last menstrual period 46 90 day dose CERVARIX . Subjects Investigator believe comply requirement protocol ( e.g . available phone interview ) . Or subject Investigator believe parent ( ) /legally acceptable representative ( ) comply requirement protocol . For Nonexposed vaccinated cohort : Written inform consent , assent case minor , obtain subject/from parent ( ) /legally acceptable representative ( ) subject . Aged , include , 15 25 year age . Residing within US Canada . Subjects receive least one dose CERVARIX least one dose GARDASIL . Gestational age inclusion 19 complete week ( i.e . 133 day gestation ) less . Last menstrual period 120 day 18 month last dose CERVARIX/ GARDASIL . Subjects Investigator believe comply requirement protocol ( e.g . available phone interview ) . Or subject Investigator believe parent ( ) /legally acceptable representative ( ) comply requirement protocol . For Exposed vaccinated cohort : Last menstrual period 30 day 90 day GARDASIL dose . Ongoing pregnancy foetus know nonviable . Ongoing pregnancy preenrolment knowledge prenatal diagnosis major structural defect . Use investigational nonregistered product ( drug vaccine ) study period . For Nonexposed vaccinated cohort : Ongoing pregnancy foetus know nonviable . Ongoing pregnancy preenrolment knowledge prenatal diagnosis major structural defect . Use investigational nonregistered product ( drug vaccine ) study period .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>vaccine</keyword>
	<keyword>Spontaneous abortion</keyword>
	<keyword>Human papillomavirus</keyword>
	<keyword>HPV</keyword>
	<keyword>Cervarix</keyword>
	<keyword>pregnancy</keyword>
</DOC>